DRMA vs JANX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 02, 2026
DRMA
61.1
AI Score
VS
JANX Wins
JANX
70.7
AI Score
Investment Advisor Scores
JANX
71score
Recommendation
BUY
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | DRMA | JANX | Winner |
|---|---|---|---|
| Net Income | -4.81M | -46.33M | DRMA |
| Operating Income | -4.94M | -65.90M | DRMA |
| ROE | -138.0% | -5.0% | JANX |
| ROA | -90.5% | -4.6% | JANX |
| Total Assets | 5.32M | 1.01B | JANX |
| Cash | 4.41M | 27.77M | JANX |
| Current Ratio | 3.40 | 16.35 | JANX |
| Free Cash Flow | -5.01M | -328,000 | JANX |
Relative Price Performance (Last 90 Days)
DRMA 1M: -14.6%
· 3M: -17.2%
JANX 1M: -10.2%
· 3M: +9.1%
Current Technical Phase
DRMA
MarkdownSell / avoid
Price below a falling SMA50 (slope -4.5%), weak momentum, RSI 40
JANX
NeutralHold
Mixed signals - no dominant trend phase, RSI 48
Fundamentals Snapshot
| Metric | DRMA | JANX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -0.8 | -6.5 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 21.8% |
| Gross Margin | — | -4.2% |
| Operating Margin | 0.0% | -3.1% |
| EPS | -4.20 | -1.67 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, JANX is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.